Objectives: studying the seroprevalence of HBsAg and anti-HCV in patients with hepatocellular carcinoma (HCC) and neoplasm of non-liver organs. Subjects and method: 124 patients with HCC and 284 patients with neoplasm of non-liver organs (i.e. stomach, colorectus and lung) were treated at Bach Mai Hospital and Viet Duc Hospital. This cross-sectional study was conductedfrom January 2002 to April 2003. Results: Out of 124 patients with HCC, HBsAg positive found in 95/124 (76.6%), anti- HCV positive found in 2/61 (3.28%), both HBsAg and anti-HCV posititive found in 1/61 (1.64%), and prevalence of anti-HCV is much lower than that of HBsAg, p<0.0001. Out of 284 patient with non-liver cancer, HBsAg posititive found in 33/284 (11.62%), and none among 179 patients has anti-HCV posititive. The prevalence of HBsAg posititive in HCC group is much higher than in non-liver cancer group (p<0.0001, OR=24.92).
Carcinoma, Hepatocellular, Neoplasms

Intra-cardiac extension of hepatocellular carcinoma (HCC) is an uncommon but serious condition related to poor prognosis. We report a 57-year-old male diagnosed with HCC with intra-cardiac extension into the right atrium at presentation. There were no symptoms related to cardiac involvement and intra-cardiac extension was incidentally noted on radiological imaging. He was offered palliative treatment and succumbed to his disease within 50 days of first diagnosis.
Carcinoma, Hepatocellular ; Liver Neoplasms

Carcinoma, Hepatocellular ; Humans ; Liver Neoplasms

Carcinoma, Hepatocellular ; Humans ; Liver Neoplasms

Sarcomatous hepatocellular carcinoma (HCC) is a rare primary liver cancer. Pathogenesis of sarcomatous transformation of HCC has not yet been elucidated. Sarcomatous HCC has highly invasive and metastatic potential, compared with ordinary HCC. We present here two cases of sarcomatous hepatocellular carcinoma with an unfavorable prognosis. Other cases reported in Korean literature of this uncommon tumor were also reviewed.
Carcinoma, Hepatocellular ; Liver Neoplasms ; Prognosis

Review and update some knowledge of alpha feto-protein (AFP) value in the diagnosis, prognosis and management of patients with hepatocellular carcinoma (HCC), and the role of AFP in monitoring of response to medical and surgical treatments. Serum AFP tests give sensitivity of 50% and specificity >90% at cut-off value of 500 ng/ml in the diagnosis of HCC in patients who had underlined hepatic diseases
Carcinoma, Hepatocellular ; Liver ; Liver Neoplasms

Carcinoma, Hepatocellular ; Humans ; Liver Neoplasms

Gene expression of nm23 has been investigated in many kinds of tumors, including breast cancers, colon cancers, hepatocellular carcinomas, papillary carcinomas of the thyroid and malignant melanomas since the nm23 was dislovered by Dr. Steeg as a tumor metastatic suppressor gene. Reduced expression of nm23 gene implicated in high metastatic potential in a variety of malignancies. However, there have been only a few reports on genetic alteration and expression of nm23 in human gastric carcinomas even though gastric carcinoma is a leading malignancy in Korea. In this study, we examined the expression of nm23 protein by immunohistochemistry in advanced and early gastric carcinomas, adenomas, matching normal mucosa to elucidate the role of nm23 in the development, progression and metastasis of human gastric carcinomas. The results are as follows; 1) Nm23 was expressed in 39 cases(69.6%) of 56 advanced gastric carcinomas. Among them, strong positive cases(grade 3) were 26(46.4%) and weak positive cases(grade 2) were 13(23.2%). 2) Nm23 expression was significantly different (P<0.05) depending on the site of the neoplasm. Antral carcinomas showed grade3 positivity in the 22/37 cases(60%), but carcinomas of the body showed negative (grade 1) result in about half(42.1%). 3) Nm23 expression was more intense in the neoplasm than normal mucosa.(67.9%) 4) Nm23 expression was not significantly related to the lymph node metastasis, invasion of lymphatics or veins and depth of invasion. 5) In the well differentiated carcinomas, grade3 were more common(64.0%). But in cases of signet ring cell carcinoma, many cases were negative(50.0%). 6) Nm23 expression rate and intensity was significantly increased from the normal mucosa to the gastric adenomas, early gastric carcinomas and advanced gastric carcinomas.
Humans ; Carcinoma, Hepatocellular ; Neoplasm Metastasis ; Breast Neoplasms

BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) with Barcelona Clinic Liver Cancer (BCLC) intermediate stage includes a highly heterogeneous population. Here, we aimed to sub-classify hepatocellular carcinoma with BCLC intermediate stage for better prognostification. METHODS: Between 2003 and 2008, 325 patients who were newly diagnosed as HCC with BCLC intermediate stage were considered eligible. Tumor factor and liver function were used for sub-classification. Overall survival (OS) was analyzed using Kaplan-Meier method with a comparison by log-rank test. RESULTS: A total of 325 patients with intermediate stage HCC were analyzed. Patients with tumor size ≥7 cm, tumor number ≥4 and Child-Pugh class B had the worse OS compared to those with tumor size <7 cm, tumor number <4 and Child-pugh class A, respectively (all P<0.05). These three variables affected the OS independently from multivariate Cox regression analysis (all P<0.05). So, using these three variables, patients were finally sub-classified as those with fulfilling none of three factors (B-a), one of three factors (B-b), two of three factors (B-c) and all of three factors (B-d) with the median OS of 39.2, 20.6, 12.0 and 8.3 months with statistical significances (all P<0.05 between B-a and B-b, between B-b and B-c, and between B-c and B-d), respectively. CONCLUSIONS: Sub-classification of HCC with BCLC intermediate stage may be useful in not only prognostification but also guidance of treatment strategies.
Carcinoma, Hepatocellular* ; Humans ; Liver Neoplasms* ; Liver* ; Prognosis

Carcinoma, Hepatocellular ; Liver Neoplasms ; NF-kappa B